Real world data essential for CAR-T therapy success – pharmaphorum
pharmaphorum |
Real world data essential for CAR–T therapy success
pharmaphorum Novartis looks like it will get its chimeric antigen receptor T–cell (CAR-T) therapy to market ahead of rival Kite in blood cancer. The therapy involves harvesting a patient's own T–cells and genetically modifying them to attack cancer – a process that … |
